(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/078179 A1

(51) International Patent Classification:
A61K 31/4155 (2006.01) *A61K 9/20* (2006.01)
A61K 47/38 (2006.01) *A61K 9/48* (2006.01)
A61K 9/14 (2006.01)

(21) International Application Number:
PCT/CN2022/128315

(22) International Filing Date:
28 October 2022 (28.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/275,076 03 November 2021 (03.11.2021) US

(71) Applicant: **BEIJING INNOCARE PHARMA TECH CO., LTD.** [CN/CN]; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN).

(72) Inventor: **CHEN, Xiangyang**; Bldg. 8, No. 8 Life Science Park Rd., Changping District, Beijing 102206 (CN).

(74) Agent: **INTELIGHT IP LAW FIRM**; Suite 1710, Tower B, Techart Plaza, No. 30 Xueyuan Road, Haidian District, Beijing 100083 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: AMORPHOUS SOLID DISPERSION COMPRISING (S) -1- (1-ACRYLOYLPYRROLIDIN-3-YL) -3- ((3, 5-DIMETHOXYPHENYL) ETHYNYL) -5- (METHYLAMINO) -1H-PYRAZOLE-4-CARBOXAMIDE




FIG. 4

(57) Abstract: The present invention provides an amorphous solid dispersion comprises (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ((3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide (Compound I) and a pharmaceutically acceptable polymer, and a pharmaceutical composition comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides better solubility and bioavailability when comparing with a crystalline form.

WO 2023/078179 A1